SLC5A2 and chronic kidney disease: Slowing chronic kidney disease (CKD) progression and avoiding end-stage kidney disease (ESKD, i.e., the need for dialysis or kidney transplantation) is highly desirable, given the associated adverse effects on quality of life, cardiovascular morbidity and mortality, and high economic costs.1,2 The EMPA-KIDNEY trial was established to assess the efficacy and safety of sodium glucose co-transporter-2 (SGLT2) inhibition with empagliflozin in a broad range of patients with CKD at risk of progression.